Revised disclosure pertaining to the demise of Dr. Alaka Keshav Deshapande ,pursuant to the observation email received from BSE
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.2 pts more than Nifty Microcap 250 and 1.5 pts more than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Aspira Pathlab & Diagnostics informed the BSE about the passing of Dr. Alaka Keshav Deshpande, an Independent Director, on December 30, 2025. She was also a member of three key board committees — Audit, Nomination & Remuneration, and Stakeholder Relationship. The original disclosure was filed on January 2, 2026, three days after her death, which triggered an observation email from BSE on January 5, 2026 citing a delay beyond the 24-hour SEBI LODR requirement. The company has now submitted a revised disclosure explaining that the Managing Director, Dr. Pankaj Shah, verbally informed the Compliance Officer only on January 2, 2026, and that the delay was inadvertent with no intention to withhold information.
For shareholders, this is a governance flag — a delayed disclosure drew regulatory attention from BSE, which may affect short-term sentiment. The loss of an Independent Director also means the board and three key committees need reconstitution, which could impact decision-making until a replacement is appointed.